- Home
- CBNK vs AUTL Comparison
CBNK vs AUTL Comparison
Compare CBNK & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBNK | AUTL |
|---|---|---|
| Founded | 1974 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.4M | 433.8M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CBNK | AUTL |
|---|---|---|
| Price | $29.01 | $1.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $34.00 | $8.33 |
| AVG Volume (30 Days) | 50.4K | ★ 3.9M |
| Earning Date | 01-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 26.24 | N/A |
| EPS | ★ 2.95 | N/A |
| Revenue | ★ $222,152,000.00 | $51,128,000.00 |
| Revenue This Year | $44.59 | $658.11 |
| Revenue Next Year | $6.44 | $91.34 |
| P/E Ratio | $9.85 | ★ N/A |
| Revenue Growth | 40.71 | ★ 406.67 |
| 52 Week Low | $24.69 | $1.11 |
| 52 Week High | $36.40 | $2.80 |
Technical Indicators
Market Signals| Indicator | CBNK | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 64.58 |
| Support Level | $28.86 | $1.56 |
| Resistance Level | $30.18 | $1.69 |
| Average True Range (ATR) | 0.66 | 0.10 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 44.73 | 86.96 |
Price Performance
Historical ComparisonAbout CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.